Tag
Directory:
Tags:
Directory:
Tags:
Nazir Rampersaud
Research ScientistDr. Nazir Rampersaud is a research fellow at the UCL School of Pharmacy specializing in the development and testing of novel compounds for the treatment of Parkinson's disease. More specifically, Dr. Rampersaud's current research entails examining Exendin-4, a glucagon-like peptide 1 receptor agonist, in the treatment of both motor and nonmotor symptoms of Parkinson pathology. His research has been funded by Parkinson's UK, the Cure Parkinson's Trust, and the Michael J. Fox foundation.
view this profile
Parkinson’s disease is a progressive degenerative neurological movement disorder, which affects between six and 10 million people worldwide. In the US, the combined direct and indirect costs of Parkinson’s disease is estimated to be nearly US$25 billion per year. Medication costs for an individual person with Parkinson’s is on average US$2,500 a year and therapeutic surgery, such as deep brain stimulation, can cost up to US$100,000 dollars per patient.